在COVID-19大流行期间腹腔透析患者中,Roxadustat与ESA的有效性:一项回顾性研究
Jie Liu1, Kefan Zhou2, Chen Meng1
1Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou , China.
PloS one
|March 26, 2025
概括
在COVID-19大流行期间,Roxadustat有效地治疗了腹膜透析患者的贫血,与红色素形成刺激剂 (ESA) 相比,显示出更好的药物坚持和较低的COVID-19相关死亡率.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
背景情况:
- 由于COVID-19大流行,腹透析 (PD) 患者的贫血管理变得复杂.
- 这项研究比较了roxadustat与红色形成刺激剂 (ESAs) 在流行期间治疗PD患者的贫血.
研究的目的:
- 为了比较roxadustat与ESAs在患有脏贫血的PD患者中的疗效,成本效益,药物坚持和COVID-19相关的临床结果.
主要方法:
- 在COVID-19爆发期间 (2022年12月 - 2023年1月) 在中国进行的一项单中心,回顾性研究.
- 接受PD的患者被分为两组:roxadustat (n=34) 和ESA (n=120).
- 在9个月的随访期间,分析了包括血红蛋白水平,治疗成本,药物坚持 (莫里斯基分数) 和COVID-19相关的感染和死亡率在内的结果.
主要成果:
- 罗克萨杜沙特和ESA都有效地增加了PD患者的血红蛋白水平.
- 罗沙沙斯塔特组的药物坚持改善,并减少了对贫血纠正的额外成本.
- 值得注意的是,roxadustat组的COVID-19感染和死亡率较低.
结论:
- 在COVID-19大流行期间,Roxadustat和ESA都有效治疗PD患者的贫血.
- 罗沙杜沙特在药物遵守和降低相关成本方面表现出优势.
- 在roxadustat组经历了更好的临床结果关于COVID-19感染和死亡率.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
138
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
138
Dialysis
244
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
244
Renal Failure: Dose Adjustments
50
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
50


